Moderate] Although estrogens have generally favorable effects on plasma lipids, including increases in HDL and decreases in total cholesterol and LDL, they have also been associated with significant elevations in triglyceride levels, particularly when high dosages are used. After daily administration, the spray formulations of estradiol reach steady state within 7-8 days. After 3 sprays daily, Cmax is about 54 pg/mL with a Tmax of 20 hours. AUC is about 471 pg•hr/mL. Climara Forte should be applied immediately after opening the pouch and removing the protective liner. Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk.

replying to a question/request concerning products, cooperation or business of Aflofarm – the legal basis for processing is your consent or a legitimate interest of the Controller – Article 6(1)(a) and (f) of the GDPR; Table 2 provides a summary of estradiol pharmacokinetic parameters determined during evaluation of the Climara Forte transdermal system. Calcium carbonate, soybean extract, bulking agent: cellulose, glazing agent: hydroxypropyl methylcellulose, hop cone extract, glazing agent: magnesium salts of fatty acids, cholecalciferol, ground linseed, bulking agent: sodium carboxymethylcellulose, alpha-crosslinked succinose tocopheryl, dye: titanium dioxide, glazing agent: hydroxypropylcellulose, pyridoxine hydrochloride, pteroylmonoglutamic acid, dyes: quinoline yellow and sunset yellow FCF, glazing agents: beeswax and carnauba wax. c) Adverse reactions occurring in placebo group in Climara Forte trial of clinical efficacy versus placebo In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in year 1 and persisted. Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately.In women with pre-existing hypertriglyceridemia, estrogen therapy may be associated with elevations of plasma triglycerides leading to pancreatitis. Consider discontinuation of treatment if pancreatitis occurs. Hepatic Impairment And/Or Past History Of Cholestatic Jaundice

Swimming, bathing, or using a sauna while using Climara Forte has not been studied, and these activities may decrease the adhesion of the system and the delivery of estradiol. Climea forte содржи изофлавони од соја збогатени со лен, кој помага за контрола на телесната тежина и екстракт од хмељ, благодарение на кој ги ублажува симптомите на менопауза. Дополнително, додатокот во исхраната Climea forte содржи калциум и витамин Д3, кои помагаат за одржување на здрави коски и витамин Б6, придонесувајќи за намалување на замор и замор во менопаузата. Индикации Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. isoflavones from soya - 60 mg Calcium - 400 mg, vitamin D3 - 5 mg, vitamin B6- 1.4 mg Vitamin E 12 mg equivalent of alpha-tocopherol, folic acid - 200 mg Other ingredients: Calcium carbonate cellulose (bulking), soy isoflavones, hydroxypropyl methylcellulose (glazing agent), extract of hops, succinate, D-alpha-tocopheryl acetate, magnesium salts of fatty acids (glazing agent), flaxseed ground, sodium carboxymethylcellulose, cross-linked (bulking agent), carbon titanium (dye), hydroxypropyl cellulose (glazing agent), cholecalciferol, pyridoxine hydrochloride, folic acid, quinoline yellow (color), sunset yellow FCF (dye), beeswax and carnauba wax (glazing agents) .This material includes yellow quinoline yellow and orange. The product contains soy and derivatives.Climara Forte has also been shown to exert favorable effects on bone density by inhibiting bone resorption. Estrogen appears to inhibit bone resorption and may have beneficial effects on the plasma lipid profile. Estrogens cause an increase in hepatic synthesis of various proteins, which include sex hormone binding globulin (SHBG), and thyroid-binding globulin (TBG). Estrogens are known to suppress the formation of follicle-stimulating hormone (FSH) in the anterior pituitary gland. Dose proportionality was demonstrated for the Climara Forte 6.5 cm² transdermal system as compared to the Climara Forte 12.5 cm² transdermal system in a 2-week crossover study with a 1-week washout period between the two-transdermal systems in 24 postmenopausal women. Mamy podaną konkretną ilość tych fitohormonów – czyli izoflawonów z nasion soi – na plus – to najważniejszy składnik Climei Forte. Start therapy with 0.025 mg per day applied to the skin once weekly. The dose should be adjusted as necessary to control symptoms. Clinical responses (relief of symptoms) at the lowest effective dose should be the guide for establishing administration of the Climara Forte transdermal system, especially in women with an intact uterus. Prevention Of Postmenopausal Osteoporosis Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is a major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the intestine followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens. Excretion